Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shinva Medical Instrument Co., Ltd. (600587.SS)
Zibo, CN
Established in 1943 and headquartered in Zibo, China, Shinva Medical Instrument Co., Ltd. is a prominent provider of medical instruments and equipment within the People's Republic of China. The company's extensive product portfolio spans a wide array of specialized areas. These include comprehensive solutions for central sterile supply departments (CSSD), pharmaceutical manufacturing, radiotherapy, and digital operating rooms. They also cater to dental practices, medical environmental protection, and experimental animal care. Furthermore, their range encompasses in vitro diagnostic reagents and instruments, as well as biomedical materials and supplies. Beyond these, Shinva also manufactures pharmaceutical machinery and air purification systems.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.36% | -0.29% | -5.14% | -10.89% | -12.54% | -5.07% | -11.06% | -45.90% | -19.82% | -22.24% | +153.62% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-2.8% Q1'26: -2.3% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-23.7% Q1'26: -25.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+3.1% ★ Q1'26: +2.2% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+6.5% ★ Q1'26: +7.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+9.5% ★ Q1'26: +8.3% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.3% ★ Q1'26: +4.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.23× ★ Q1'26: 2.27× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.55B
est: 7.60B (-0.5%)
|
8.36B
est: 8.27B (+1.2%)
|
9.98B
est: 9.74B (+2.5%)
|
10.28B
est: 11.22B (-8.4%)
|
8.77B
est: 12.50B (-29.9%)
|
9.15B
est: 24.04B (-61.9%)
|
9.48B
est: 9.99B (-5.1%)
|
9.28B
est: 9.74B (-4.7%)
|
10.01B
est: 10.01B (0.0%)
|
10.02B
est: 10.43B (-3.9%)
|
9.74B
est: 10.82B (-10.1%)
|
11.58B
11.58B – 11.58B
+7.0% YoY
|
12.38B
12.38B – 12.38B
+6.9% YoY
|
| EBITDA |
721.98M
est: 615.18M (+17.4%)
|
505.88M
est: 669.65M (-24.5%)
|
628.02M
est: 789.03M (-20.4%)
|
624.16M
est: 909.12M (-31.3%)
|
1.48B
est: 1.01B (+46.3%)
|
647.93M
est: 1.95B (-66.7%)
|
972.15M
est: 809.37M (+20.1%)
|
824.36M
est: 789.23M (+4.5%)
|
972.68M
est: 810.91M (+19.9%)
|
1.03B
est: 1.00B (+2.8%)
|
865.98M
est: 1.04B (-16.7%)
|
1.11B
1.11B – 1.11B
+7.0% YoY
|
1.19B
1.19B – 1.19B
+6.9% YoY
|
| EBIT |
616.48M
est: 469.70M (+31.2%)
|
373.05M
est: 511.28M (-27.0%)
|
474.73M
est: 602.44M (-21.2%)
|
438.15M
est: 694.12M (-36.9%)
|
1.29B
est: 773.30M (+67.4%)
|
469.33M
est: 1.49B (-68.4%)
|
795.41M
est: 617.96M (+28.7%)
|
635.13M
est: 602.59M (+5.4%)
|
785.65M
est: 619.14M (+26.9%)
|
843.65M
est: 792.52M (+6.5%)
|
632.53M
est: 822.50M (-23.1%)
|
880.10M
880.10M – 880.10M
+7.0% YoY
|
940.81M
940.81M – 940.81M
+6.9% YoY
|
| Net Income |
280.83M
est: 346.87M (-19.0%)
|
34.64M
est: 304.11M (-88.6%)
|
65.53M
est: 43.66M (+50.1%)
|
22.78M
est: 159.88M (-85.7%)
|
861.31M
est: 299.59M (+187.5%)
|
234.14M
est: 228.67M (+2.4%)
|
556.49M
est: 604.34M (-7.9%)
|
500.07M
est: 581.78M (-14.0%)
|
654.00M
est: 714.01M (-8.4%)
|
691.61M
est: 725.98M (-4.7%)
|
526.34M
est: 798.58M (-34.1%)
|
883.28M
883.28M – 883.28M
+10.6% YoY
|
949.82M
949.82M – 949.82M
+7.5% YoY
|
| SGA |
974.81M
est: 1.04B (-5.9%)
|
1.15B
est: 1.13B (+1.9%)
|
1.20B
est: 1.33B (-9.5%)
|
1.28B
est: 1.53B (-16.2%)
|
1.32B
est: 1.70B (-22.6%)
|
1.27B
est: 3.28B (-61.2%)
|
1.31B
est: 1.36B (-4.1%)
|
1.34B
est: 1.33B (+0.8%)
|
1.33B
est: 1.36B (-2.6%)
|
1.28B
est: 1.22B (+5.0%)
|
409.54M
est: 1.27B (-67.6%)
|
1.35B
1.35B – 1.35B
+7.0% YoY
|
1.45B
1.45B – 1.45B
+6.9% YoY
|
| EPS |
0.53
est: 0.57 (-7.3%)
|
0.07
est: 0.50 (-86.2%)
|
0.12
est: 0.07 (+66.7%)
|
0.05
est: 0.26 (-82.5%)
|
1.63
est: 0.49 (+230.1%)
|
0.45
est: 0.38 (+19.4%)
|
1.05
est: 1.00 (+5.4%)
|
0.95
est: 0.96 (-0.9%)
|
1.10
est: 1.18 (-6.5%)
|
1.14
est: 1.20 (-5.0%)
|
0.87
est: 1.32 (-34.1%)
|
1.46
1.46 – 1.46
+10.6% YoY
|
1.57
1.57 – 1.57
+7.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 65.6K | 0.46% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 265.3K | 0.39% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 307.7K | 0.06% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 86.0K | 0.29% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 25.2K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.2K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.25M | 0.06% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 58.6K | 0.28% |
| 9 | Vanguard Total World Stock ETF VT | 0.00% | 198.2K | 0.06% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.15M | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baoxian Gong | General Manager | — | male |
| Cai Xiang Li | Deputy GM & Secretary of the Board | — | male |
| Hai Yun Yao | Accounting Supervisor | — | — |
| Jiaqiang Wang | Deputy General Manager | — | male |
| Jing Qu | Deputy General Manager | — | male |
| Juanjuan Zhou | Chief Financial Officer & Director | — | female |
| Qingguo Zhu | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600587.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
